Put companies on watchlist
CompuGroup Medical SE & Co. KGaA
ISIN: DE000A288904
WKN: A28890
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

CompuGroup Medical SE & Co. KGaA · ISIN: DE000A288904 · EQS - adhoc news (73 News)
Country: Germany · Primary market: Germany · EQS NID: 1473983
27 October 2022 07:26PM

CompuGroup Medical SE & Co. KGaA adjusts guidance for the financial year 2022


EQS-Ad-hoc: CompuGroup Medical SE & Co. KGaA / Key word(s): Change in Forecast
CompuGroup Medical SE & Co. KGaA adjusts guidance for the financial year 2022

27-Oct-2022 / 19:26 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


The general partner of CompuGroup Medical SE & Co. KGaA (the “Company”) (ISIN: DE000A288904 | WKN: A28890) announces that today it has once again reviewed the guidance for the current financial year 2022 and, due to the postponement of projects (in particular of the PTV5-update) into the financial year 2023, adjusted the guidance for the adjusted operative earnings (EBITDA, as defined in the 2021 annual report of the Company) to EUR 220 million to EUR 240 million (previously EUR 240 million to EUR 260 million), and for the adjusted earnings per share (as defined in the 2021 annual report of the Company) to EUR 1.70 to EUR 1.90 (previously EUR 1.90 to EUR 2.10). The free cashflow (as defined in the 2021 annual report of the Company) is now forecasted to be in a range between EUR 40 million and EUR 70 million (previously over EUR 100 million). The Company now expects revenues for the current financial year 2022 to be in a range between EUR 1,100 million and EUR 1,130 million (previously EUR 1,100 million to EUR 1,150 million). Preliminary revenues for the first nine months of the current financial year 2022 are expected to be EUR 802 million with adjusted operating earnings (EBITDA, as defined in the 2021 annual report of the Company) of EUR 166 million.

CompuGroup Medical SE & Co. KGaA will publish its results for the first nine months of the current financial year 2022 as scheduled on November 3, 2022.

 


27-Oct-2022 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany
Phone: +49 (0)160 3630362
Fax: +49 (0)261 8000 3200
E-mail: investor@cgm.com
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1473983

 
End of Announcement EQS News Service

1473983  27-Oct-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1473983&application_name=news&site_id=boersengefluester_html
Visual performance / price development - CompuGroup Medical SE & Co. KGaA
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.